PT2877173T - Antagonistas/agonistas inversos de recetor de canabinoides - Google Patents

Antagonistas/agonistas inversos de recetor de canabinoides

Info

Publication number
PT2877173T
PT2877173T PT138227475T PT13822747T PT2877173T PT 2877173 T PT2877173 T PT 2877173T PT 138227475 T PT138227475 T PT 138227475T PT 13822747 T PT13822747 T PT 13822747T PT 2877173 T PT2877173 T PT 2877173T
Authority
PT
Portugal
Prior art keywords
receptor antagonists
inverse agonists
cannabinoid receptor
cannabinoid
agonists
Prior art date
Application number
PT138227475T
Other languages
English (en)
Original Assignee
Jenrin Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenrin Discovery Inc filed Critical Jenrin Discovery Inc
Publication of PT2877173T publication Critical patent/PT2877173T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT138227475T 2012-07-25 2013-07-25 Antagonistas/agonistas inversos de recetor de canabinoides PT2877173T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261675806P 2012-07-25 2012-07-25
US201361787214P 2013-03-15 2013-03-15
US13/950,195 US8680131B2 (en) 2012-07-25 2013-07-24 Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers

Publications (1)

Publication Number Publication Date
PT2877173T true PT2877173T (pt) 2020-02-21

Family

ID=49995474

Family Applications (1)

Application Number Title Priority Date Filing Date
PT138227475T PT2877173T (pt) 2012-07-25 2013-07-25 Antagonistas/agonistas inversos de recetor de canabinoides

Country Status (16)

Country Link
US (6) US8680131B2 (pt)
EP (1) EP2877173B1 (pt)
JP (1) JP6249534B2 (pt)
CN (2) CN104640543A (pt)
AU (1) AU2013295741B2 (pt)
CA (1) CA2879741C (pt)
DK (1) DK2877173T3 (pt)
ES (1) ES2771323T3 (pt)
HR (1) HRP20200212T1 (pt)
HU (1) HUE048386T2 (pt)
IL (1) IL236789A (pt)
IN (1) IN2015DN01503A (pt)
MX (1) MX364912B (pt)
PL (1) PL2877173T3 (pt)
PT (1) PT2877173T (pt)
WO (1) WO2014018695A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8680131B2 (en) 2012-07-25 2014-03-25 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers
US9837765B2 (en) * 2015-06-25 2017-12-05 Microsoft Technology Licensing, Llc Apparatus for ejecting at least one integrated circuit card
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255093A1 (en) 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
MXPA02009258A (es) 2000-03-23 2005-04-19 Solvay Pharm Bv Derivados de 4,5-dihidro-1h-pirazol que tienen actividad antagonistica de cannabis-1.
SI1373216T1 (en) 2001-03-22 2005-06-30 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
DK1429761T3 (da) 2001-09-21 2007-02-05 Solvay Pharm Bv Hidtil ukendte 4,5-dihydro-1H-pyrazolderivater med CB1-antagonistisk virkning
KR100950430B1 (ko) 2001-09-21 2010-04-02 솔베이 파마슈티칼스 비. 브이 효력있는 cb1-길항 작용을 가지는4,5-디하이드로-1h-피라졸 유도체
AU2007247878B2 (en) 2006-05-05 2012-05-31 Jenrin Discovery Cannabinoid receptor antagonists/inverse agonists
US7655685B2 (en) * 2007-11-02 2010-02-02 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
CN103547263B (zh) * 2010-11-18 2015-12-09 詹里恩探索公司 对于治疗代谢性疾病,包括肥胖症和糖尿病有用的大麻素受体拮抗剂/反相激动剂
US8680131B2 (en) * 2012-07-25 2014-03-25 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers

Also Published As

Publication number Publication date
CN104640543A (zh) 2015-05-20
IL236789A (en) 2017-07-31
AU2013295741B2 (en) 2017-05-04
HUE048386T2 (hu) 2020-07-28
DK2877173T3 (da) 2020-02-24
US9133127B2 (en) 2015-09-15
AU2013295741A1 (en) 2015-03-12
US9987253B2 (en) 2018-06-05
CA2879741A1 (en) 2014-01-30
US8680131B2 (en) 2014-03-25
US11179370B2 (en) 2021-11-23
US20180353478A1 (en) 2018-12-13
US20140031404A1 (en) 2014-01-30
WO2014018695A1 (en) 2014-01-30
US10617673B2 (en) 2020-04-14
MX364912B (es) 2019-05-13
CA2879741C (en) 2020-09-29
HRP20200212T1 (hr) 2020-10-16
JP2015523396A (ja) 2015-08-13
EP2877173A1 (en) 2015-06-03
IN2015DN01503A (pt) 2015-07-03
ES2771323T3 (es) 2020-07-06
EP2877173A4 (en) 2016-03-16
CN110372593A (zh) 2019-10-25
US20210023054A1 (en) 2021-01-28
US20170182004A1 (en) 2017-06-29
US20140329875A1 (en) 2014-11-06
JP6249534B2 (ja) 2017-12-20
US20160058736A1 (en) 2016-03-03
US9517228B2 (en) 2016-12-13
PL2877173T3 (pl) 2020-08-10
EP2877173B1 (en) 2019-11-13
MX2015001014A (es) 2015-08-14

Similar Documents

Publication Publication Date Title
HK1252279A1 (zh) 5- ht3受體拮抗劑
HK1203191A1 (en) P2x4 receptor antagonist p2x4
EP2964226A4 (en) 2-pyridyloxy-4-ESTER-orexin receptor antagonists
EP2911675A4 (en) 2-PYRIDYLOXY-3-SUBSTITUTED 4-NITRIL-OREXINE RECEPTOR ANTAGONISTS
EP2934527A4 (en) ANTAGONIST 2-PYRYDYLOXY-4-ESTER COMPOUNDS OF OREXIN RECEPTORS
EP2934516A4 (en) ANTAGONISTS OF 3-ESTER-4-SUBSTITUTED OREXIN RECEPTORS
EP2925321A4 (en) 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
EP2934517A4 (en) 4-SUBSTITUTED 2-PYRYDYLOXY-3-NITRILE OREXIN RECEPTOR ANTAGONISTS
EP2908812A4 (en) 2-pyridyloxy, 3-ESTER-4-NITRILOREXIN receptor antagonists
HK1205706A1 (zh) 受體激動劑
HK1202546A1 (en) Novel adamantyl derivatives as cannabinoid receptor agonists
EP2877173A4 (en) ANTAGONISTS / INVERSE AGONISTS OF CANNABINOID RECEPTORS
EP2872138A4 (en) NEUROPROTECTIVE AGONISTS OF CB2 RECEPTORS
IL243730A0 (en) Vasopressin-2 receptor agonists
GB201312010D0 (en) Receptor Agonists
GB201213699D0 (en) Receptor antagonists II
GB201213698D0 (en) Receptor antagonists II
GB201216854D0 (en) Agonist